ATH
ALTERITY THERAP LTD ORDINARYAlterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
ATH
ATH
ALTERITY THERAP LTD ORDINARY
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.10% | — |
| 24 Aug | 0.10% | — |
| 21 Aug | 0.10% | — |
| 20 Aug | 0.10% | — |
| 19 Aug | 0.00% | — |
| 18 Aug | 0.00% | — |
| 17 Aug | 0.00% | — |
| 14 Aug | 0.00% | — |
| 13 Aug | 0.00% | — |
Alterity Therap LTD (ATH) Short Interest Summary
Alterity Therap LTD (ATH) currently has 0.10% of its shares sold short (211 thousand shares, worth approximately $110K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes ATH the #453 most shorted stock on the ASX most shorted list. Short interest in ATH is up 0.09% over the past week and up 0.10% over the past month. ATH is part of the Health Care sector on the ASX.
Recent ATH Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.10% | 0.2M | $0.51 |
| 24 Aug 2026 | 0.10% | 0.2M | $0.50 |
| 21 Aug 2026 | 0.10% | 0.2M | $0.49 |
| 20 Aug 2026 | 0.10% | 0.2M | $0.50 |
| 19 Aug 2026 | 0.00% | 0.0M | $0.50 |
| 18 Aug 2026 | 0.00% | 0.0M | $0.50 |
| 17 Aug 2026 | 0.00% | 0.0M | $0.53 |
| 14 Aug 2026 | 0.00% | 0.0M | $0.55 |
| 13 Aug 2026 | 0.00% | 0.0M | $0.54 |
| 12 Aug 2026 | 0.00% | 0.0M | $0.56 |
ATH Short Selling — Frequently Asked Questions
What is Alterity Therap LTD (ATH)'s current short interest?
Alterity Therap LTD (ATH) currently has a short interest of 0.10% of total shares outstanding. This means 0.10% of ATH's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is ATH heavily shorted on the ASX?
ATH has a relatively low short interest of 0.10%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for ATH investors?
Short interest in ATH shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.10%, ATH's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this ATH short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for ATH.